Regenxbio

RGNXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$530.086 M

$8.03 -2.25%

Close of 18 Sept 2026

Revenue

$170.4M

#2343 by revenue

Earnings

-$193.9M

Loss-making

Shares outstanding

66,013,192

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 159 →

#62ProkidneyPROK$577.4M
#63Prime MedicinePRME$565.9M
#64RegenxbioRGNX$530.1M
#65Tectonic TherapeuticTECX$527.8M
#66Autolus TherapeuticsAUTL$516.4M

What if Regenxbio were worth as much as…

Open the what-if tool →

Gold $30.4T

$460,324.03

Per share 57,326× higher

Bitcoin $1.64T

$24,783.35

Per share 3,086× higher

Nvidia $5.36T

$81,146.01

Per share 10,105× higher

Or at a round number

$1.00B $2.00B $5.00B $10.0B

Where these numbers come from

Share counts and financials for Regenxbio are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 19 Sept 2026. Read the methodology.